Retrospective study shows omalizumab reduces adverse reactions in pediatric asthma patients undergoing allergen immunotherapy, suggesting improved safety.
Summary OMA reduces AIT‐related adverse reactions in paediatric allergic disorders. OMA adjunctive AIT optimises therapy for high‐risk paediatric asthma patients.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: